udenafil Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
The drug udenafil is marketed under the trade name Zydena. It is within the PDE5 inhibitor class (which also includes avanafil, sildenafil, tadalafil, and vardenafil). Like other PDE5 inhibitors, it is used to treat erectile dysfunction. Udenafil was developed by Dong-A Pharmaceutical. It has fairly rapid onset of action (peak plasma concentration after 1 to 1.5 hours), and has long duration of action (plasma half-life of 11 to 13 hours). Udenafil's pharmacokinetics allows once-daily dosage (in addition to on-demand use). Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and the Philippines. It has not yet been approved for use in the United States by the U.S. Food and Drug Administration.   Wikipedia

Chemistry

  • SMILES: CCCOc1ccc(cc1C2=Nc3c(CCC)nn(C)c3C(=O)N2)S(=O)(=O)NCCC4CCCN4C
  • InChIKey: IYFNEFQTYQPVOC-UHFFFAOYSA-N
  • Mol. Mass: 516.67
  • ALogP: 2.83
  • ChEMBL Molecule:
    udenafil  
More Chemistry

Pharmacology

Alternative names

5-(2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7h-pyrazolo (4,3-d) pyrimidine-7-one | da 8159 | da-8159 | udenafil | wc3055 | zidena | zydena

Organizations (22)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (25)

Approved Indications (1)


 

Erectile Dysfunction

Experimental Indications - Clinical Trial Phases 1-4 (25)


 

Alzheimer Disease (Phase 3)

Dementia, Vascular (Phase 2)

Dyspnea (Phase 3)

Erectile Dysfunction (Phase 3)

General Surgery (Phase 1/Phase 2)

Genetic Diseases, Inborn (Phase 1)

Healthy Volunteers (Phase 1)

Heart Diseases (Phase 3)

Heart Failure, Diastolic (Phase 3)

Heart Failure, Systolic (Phase 3)

Hypertension, Pulmonary (Phase 3)

Kidney Diseases (Phase 1)

Liver Diseases (Phase 1)

Microvascular Angina (Phase 4)

Pharmacokinetics (Phase 1)

Phosphodiesterase 5 Inhibitors (Phase 1)

Prostatic Hyperplasia (Phase 2)

Pulmonary Arterial Hypertension (Phase 2/Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Raynaud Disease (Phase 2/Phase 3)

Rectal Neoplasms (Phase 4)

Renal Insufficiency (Phase 1)

Sigmoid Neoplasms (Phase 2)

Spermatogenesis (Phase 1)

Urologic Diseases (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 33
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue